Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Advanced Oncotherapy in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 1.75.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Advanced Oncotherapy. This N/A consensus rating has held steady for over two years.
Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.
Read More